1. Academic Validation
  2. Prospective evaluation of hypromellose 2% for punctal occlusion in patients with dry eye

Prospective evaluation of hypromellose 2% for punctal occlusion in patients with dry eye

  • Cornea. 2015 Feb;34(2):188-92. doi: 10.1097/ICO.0000000000000325.
Leonardo Capita 1 Maria R Chalita Leopoldo Luiz dos Santos-Neto
Affiliations

Affiliation

  • 1 *Hospital Universitário de Brasília, Universidade de Brasília (UnB), Brasília, Brazil; †Department of Ophthalmology, Universidade de Brasília UnB, Brasília, Brazil; and ‡Department of Internal Medicine, Universidade de Brasília (UnB), Brasília, Brazil.
Abstract

Purpose: The aim of this study was to evaluate the effectiveness of punctal occlusion using hypromellose 2% in patients with dry eye.

Methods: In this prospective, randomized single-blinded clinical trial, we evaluated 76 eyes of 38 patients (36 women and 2 men) with dry eye secondary to rheumatic diseases. In each patient, the lower lacrimal punctum of 1 eye was occluded using hypromellose 2%, whereas the contralateral eye underwent a simulation of the procedure (control group). Patients' eyes were assessed for burning, itching, redness, foreign body sensation, and tearing based on a visual scale questionnaire (score, 0-10). We also performed objective tests for evaluation of dry eye using a Schirmer test with anesthesia (basal tear secretion test), the tear film break-up time test, and fluorescein and rose bengal staining tests at 0, 28, and 56 days after treatment.

Results: Fluorescein and rose bengal staining tests showed that there was a significant reduction in signs after occlusion using hypromellose. The symptoms measured by the visual scale were significantly reduced. The values of the Schirmer test with anesthesia and the break-up time test increased significantly. The effects persisted for up to 8 weeks. There were no dropouts or reported side effects during the 24-month follow-up.

Conclusions: Our results suggest that punctal occlusion using hypromellose 2% is a low-cost and safe additional treatment for dry eye.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-A0104
    Excellent Excipient